A phase II trial in patients with acute promyelocytic leukaemia (APML) to evaluate the effects of: all-trans retinoic acid (ATRA) combined with intensive idarubicin during induction and consolidation; subsequent intermittent all-trans retinoic acid; and molecular monitoring for evidence of minimal residual leukaemia and for evidence of incipient relapse, as measured by remission rate, relapse rate and overall survival. (APML03)

Diagnosis and Molecular Monitoring of Acute Promyelocytic Leukemia Using DzyNA Reverse Transcription-PCR to Quantify PML/RARα Fusion Transcripts

doi : https://doi.org/10.1093/clinchem/48.8.1338

Molecular Monitoring of Acute Promyelocytic Leukemia by DzyNA Reverse Transcription-PCR

doi : https://doi.org/10.1093/clinchem/48.10.1858

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia

doi : https://doi.org/10.3324/haematol.2011.047506

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

doi : https://doi.org/10.1182/blood-2012-02-410746

Australasian Leukaemia And Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Australasian Leukaemia and Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326